About this trial

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

13
Canada
St. Joseph's Healthcare HamiltonOntario, Canada
Mount Sinai Hospital TorontoOntario, Canada
Germany
medius KLINIK KIRCHHEIM73230, Kirchheim unter Teck Germany
Italy
AOU Meyer IRCCS Florence Italy

Sponsors and collaborators

University of Pennsylvania

Lead sponsor

GlaxoSmithKline

Collaborator

AstraZeneca

Collaborator